NCT00141362
Completed
Phase 3
An Open-Label, Extension Safety and Efficacy Study of Pregabalin in Patients With Chronic Neuropathic Pain.
ConditionsPain
DrugsPregabalin
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Pain
- Sponsor
- Pfizer
- Enrollment
- 325
- Primary Endpoint
- Safety and efficacy
- Status
- Completed
- Last Updated
- 19 years ago
Overview
Brief Summary
Evaluate long-term safety and efficacy of pregabalin in patients with chronic neuropathic pain.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Must have met the inclusion criteria for the preceding double-blind BID study in diabetic neuropathy or postherpetic neuralgia.
- •Must have received study medication under double-blind conditions.
Exclusion Criteria
- •Patients cannot participate if they experienced a serious adverse event during the previous double-blind BID study which was determined to be related to the study medication.
Outcomes
Primary Outcomes
Safety and efficacy
Similar Trials
Completed
Phase 3
To Evaluate Long-Term Safety and Efficacy of Pregabalin in the Treatment of Neuropathic Pain After Spinal Cord Injury.Neuropathic PainNCT00141375Pfizer132
Completed
Phase 3
To Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Postherpetic Neuralgia.NeuralgiaNCT00150436Pfizer276
Completed
Phase 3
A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin For Pain Associated With Diabetic Peripheral NeuropathyDiabetic Neuropathy, PainfulNCT00553280Pfizer's Upjohn has merged with Mylan to form Viatris Inc.123
Terminated
Phase 3
Pregabalin Trial In HIV Neuropathic PainHIV-1 InfectionNeuropathic PainNCT01145417Pfizer's Upjohn has merged with Mylan to form Viatris Inc.217
Completed
Phase 3
A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin In Patients With FibromyalgiaFibromyalgiaNCT00830128Pfizer's Upjohn has merged with Mylan to form Viatris Inc.106